REPLAY: The Black Box of Vector-Borne Pathogens

Babesia is often present but rarely detected. In this clinical webinar, learn why standard diagnostics fall short, how pathogen biology creates testing gaps, and how to interpret discordant results with confidence.

REPLAY: Bartonella: The Blind Spot Pathogen

When Bartonella infections persist, present atypically, or defy standard testing, understanding why they are missed is critical. This webinar examines Bartonella’s stealth biology, non-traditional transmission routes, and diagnostic blind spots through clinically grounded case studies, providing actionable insight for providers navigating complex vector-borne disease presentations.

Bartonella: The Blind Spot Pathogen Clinicians Can’t Afford to Miss

Galaxy Diagnostics discusses why the blindspot pathogen Bartonella diagnosis missed

By Edward B. Breitschwerdt, DVM, Co-Founder, Galaxy Diagnostics, and Distinguished Professor Emeritus of Internal Medicine and Infectious Diseases, NC State University College of Veterinary Medicine   Summary: Bartonella is one of the most diagnostically overlooked pathogens in clinical medicine, not because it is rare, but because the standard tools used to find it (including both… Continue reading Bartonella: The Blind Spot Pathogen Clinicians Can’t Afford to Miss

Two LymeX Innovators, One Mission: Better Answers for Patients

Galaxy Dx and Virginia Tech collaborate to advance next generation Lyme disease testing.

Galaxy Diagnostics and Virginia Tech Unite to Advance Testing for Lyme Disease By Nicole Danielle Bell, CEO of Galaxy Diagnostics and author of What Lurks in the Woods When a Test Fails a Patient   When diagnostics fail patients, the consequences are real. I’ve lived it. My husband tested negative using the current standard-of-care test… Continue reading Two LymeX Innovators, One Mission: Better Answers for Patients

Two LymeX Innovators, One Mission: Advancing Reliable Lyme Diagnostics

Galaxy Dx and Virginia Tech are advancing next generation Lyme disease testing.

Galaxy Diagnostics and Virginia Tech Unite to Strengthen Direct Detection Approaches for Lyme Disease By Nicole Danielle Bell, CEO of Galaxy Diagnostics and author of What Lurks in the Woods The Diagnostic Uncertainty Clinicians Face Clinicians evaluating patients with suspected tick-borne disease routinely manage diagnostic uncertainty. Prior exposure, immune variability, and timing-dependent antibody responses can… Continue reading Two LymeX Innovators, One Mission: Advancing Reliable Lyme Diagnostics

REPLAY: Uncovering What’s Missed: Advancing Detection for Elusive Tick-Borne Infections

Standard testing leaves too many tick-borne infections undetected. This clinical webinar explores advanced detection methods to help clinicians find what’s missed when symptoms persist or contradict test results.